查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1602810

抗血管内皮生长因子治疗市场：依治疗类型、给药途径、适应症分类 - 全球预测 2025-2030

Anti-vascular Endothelial Growth Factor Therapeutics Market by Therapeutic Type (Monoclonal Antibodies, Tyrosine Kinase Inhibitors), Route of Administration (Intravitreal Injections, Oral Administration), Indication - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年抗血管内皮生长因子治疗市场估值为84.9亿美元，预计2024年将达90.1亿美元，复合年增长率为8.85%，2030年将达153亿美元，预计将达80美元百万。

抗血管内皮生长因子（VEGF）疗法在治疗与血管生长异常相关的疾病中发挥重要作用，例如老龄化黄斑部病变（AMD）、糖尿病视网膜病变和某些癌症。其作用范围是抑制参与血管生成的VEGF蛋白并阻止疾病进展。随着血管相关疾病的盛行率随着人口老化而增加，对抗 VEGF 疗法等有效治疗方法的需求变得显而易见。这些疗法主要应用于眼科和肿瘤科，为医院、诊所和专业医疗中心等最终用户提供服务。关键的成长要素包括目标疾病盛行率的增加、生技药品的进步以及有前景的化合物的强大管道。该公司将透过专注于生物相似药开发、新兴市场的地理扩张以及利用基因组见解来优化治疗结果的个人化医疗方法来抓住潜在的商机。

主要市场统计
基准年[2023] 84.9亿美元
预测年份 [2024] 90.1亿美元
预测年份 [2030] 153.8亿美元
复合年增长率（%） 8.85%

然而，市场面临着治疗成本高、专利到期导致生物相似药竞争以及与长期治疗相关的潜在副作用等挑战。监管障碍和生物製药製造的复杂性为市场扩张带来了进一步的挑战。儘管存在这些障碍，创新仍然很重要。缓释性、联合治疗和新型递送系统（例如玻璃体内注射和眼内植入）等领域代表了有前景的研究途径。此外，整合远端医疗等数位技术来监测治疗效果可以加强病患管理并减轻医疗负担。该市场的特点是动态竞争、不断进步以及大力推动常见障碍的永续解决方案。强调製药公司、学术机构和生物技术公司之间的合作研究可以加速疾病机制理解的突破以及更有效的抗VEGF疗法的研发。透过了解这些趋势并应对不断变化的监管环境，公司可以对自己进行策略性定位，以便在这个不断发展的治疗领域中实现显着成长。

市场动态：快速发展的抗血管内皮生长因子治疗市场的关键市场洞察

供需的动态交互作用正在改变抗血管内皮生长因子治疗市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 眼科疾病盛行率上升
    • 患有眼科疾病的老年人口增加
    • 提高抗 VEGF 治疗的认识
  • 市场限制因素
    • 抗 VEGF 治疗的不利报销情况
  • 市场机会
    • 持续研究活动以开发先进的治疗药物
    • 监理药品核准快速增加
  • 市场挑战
    • 抗 VEGF 治疗对眼内损伤的担忧

波特五力：开拓抗血管内皮生长因子治疗市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解抗血管内皮生长因子治疗市场的外部影响

外部宏观环境因素在塑造抗血管内皮生长因子治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解抗血管内皮生长因子治疗药物市场竞争状况

抗血管内皮生长因子治疗市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵抗血管内皮生长因子治疗市场供应商的绩效评估

FPNV定位矩阵是评估抗血管内皮生长因子治疗市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘抗血管内皮生长因子治疗市场的成功之路

抗血管内皮生长因子治疗市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 眼科疾病盛行率上升
      • 患有眼科疾病的老年人数量增加
      • 提高抗 VEGF 治疗的认识
    • 抑制因素
      • 抗 VEGF 治疗的不利报销情况
    • 机会
      • 旨在开发先进治疗方法的持续研究活动
      • 监理药品核准快速增加
    • 任务
      • 抗 VEGF 治疗对眼内损伤的担忧
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依治疗类型分類的抗血管内皮生长因子治疗药物市场

  • 单株抗体
  • 蛋白酪氨酸激酶抑制剂

第七章抗血管内皮生长因子治疗市场：依给药途径

  • 玻璃体内注射
  • 口服给药

第八章按适应症分類的抗血管内皮生长因子治疗市场

  • 糖尿病黄斑部水肿
  • 视网膜静脉阻塞
  • 湿性老龄化黄斑部病变

第九章美洲抗血管内皮生长因子治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区抗血管内皮生长因子治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东、非洲抗血管内皮生长因子治疗药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Alteogen Inc.
  • Amgen Inc.
  • Arechar Healthcare
  • Aurobindo Pharma
  • Bausch Health Companies Inc.
  • Bayer AG
  • Biogen Inc.
  • Cipla Ltd.
  • Coherus BioSciences, Inc.
  • Delphis Pharmaceutical India
  • F. Hoffmann-La Roche AG
  • Hetero Healthcare Limited
  • Intas Pharmaceuticals Ltd.
  • Natco Pharma Limited
  • Novartis AG
  • Pfenex Inc.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Samsung Bioepis
  • Sandoz Canada Incorporated
  • Shilpa Medicare Ltd.
  • Sun Pharmaceutical Industries Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Xbrane Biopharma
Product Code: MRR-B168537775F5

The Anti-vascular Endothelial Growth Factor Therapeutics Market was valued at USD 8.49 billion in 2023, expected to reach USD 9.01 billion in 2024, and is projected to grow at a CAGR of 8.85%, to USD 15.38 billion by 2030.

Anti-vascular endothelial growth factor (VEGF) therapeutics play a critical role in treating conditions related to abnormal blood vessel growth, such as age-related macular degeneration (AMD), diabetic retinopathy, and certain cancers. Their scope involves inhibiting VEGF proteins responsible for angiogenesis, thus preventing disease progression. As the prevalence of vascular-related conditions escalates with an aging population, the necessity for effective treatments like anti-VEGF therapeutics has become more pronounced. These therapies find applications primarily in ophthalmology and oncology, serving end-users such as hospitals, clinics, and specialized healthcare centers. Key growth influencers include an increasing incidence of target disorders, advancements in biologics, and a robust pipeline of promising compounds. Companies can seize potential opportunities by focusing on biosimilars development, geographic expansion in emerging markets, and personalized medicine approaches, leveraging genomic insights to optimize therapeutic outcomes.

KEY MARKET STATISTICS
Base Year [2023] USD 8.49 billion
Estimated Year [2024] USD 9.01 billion
Forecast Year [2030] USD 15.38 billion
CAGR (%) 8.85%

However, the market faces challenges, including high treatment costs, patent expiration leading to biosimilar competition, and potential adverse effects associated with long-term therapy use. Regulatory hurdles and the complexity of biologic drug manufacturing further challenge market expansion. Despite these impediments, innovation remains crucial; areas like extended-release formulations, combination therapies, and novel delivery systems such as intravitreal injections or ocular implants offer promising research avenues. Moreover, digital technology integration, like telemedicine for monitoring treatment efficacy, can enhance patient management and reduce healthcare burdens. The market is marked by dynamic competition, constant advancements, and a strong push towards sustainable solutions to commonly encountered barriers. Emphasizing collaborative research between pharmaceutical companies, academic institutions, and biotech firms can spur breakthroughs in understanding disease mechanisms and developing more effective anti-VEGF therapies. By staying attuned to these trends and adaptable to changing regulatory landscapes, businesses can strategically position themselves for substantial growth in this evolving therapeutic domain.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anti-vascular Endothelial Growth Factor Therapeutics Market

The Anti-vascular Endothelial Growth Factor Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rise in the prevalence of ophthalmic diseases
    • Increasing number of geriatric population with eye disorders
    • Growing awareness about anti-VEGF treatment
  • Market Restraints
    • Unfavorable reimbursement scenario for anti-VEGF treatment
  • Market Opportunities
    • Ongoing research activities to develop advanced therapeutics
    • Surge in drug approvals from regulatory bodies
  • Market Challenges
    • Concern regarding intraocular injuries in anti-VEGF treatment

Porter's Five Forces: A Strategic Tool for Navigating the Anti-vascular Endothelial Growth Factor Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anti-vascular Endothelial Growth Factor Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anti-vascular Endothelial Growth Factor Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anti-vascular Endothelial Growth Factor Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anti-vascular Endothelial Growth Factor Therapeutics Market

A detailed market share analysis in the Anti-vascular Endothelial Growth Factor Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anti-vascular Endothelial Growth Factor Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anti-vascular Endothelial Growth Factor Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anti-vascular Endothelial Growth Factor Therapeutics Market

A strategic analysis of the Anti-vascular Endothelial Growth Factor Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anti-vascular Endothelial Growth Factor Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Alteogen Inc., Amgen Inc., Arechar Healthcare, Aurobindo Pharma, Bausch Health Companies Inc., Bayer AG, Biogen Inc., Cipla Ltd., Coherus BioSciences, Inc., Delphis Pharmaceutical India, F. Hoffmann-La Roche AG, Hetero Healthcare Limited, Intas Pharmaceuticals Ltd., Natco Pharma Limited, Novartis AG, Pfenex Inc., Pfizer Inc., Regeneron Pharmaceuticals Inc., Samsung Bioepis, Sandoz Canada Incorporated, Shilpa Medicare Ltd., Sun Pharmaceutical Industries Inc., Teva Pharmaceutical Industries Ltd., Viatris Inc., and Xbrane Biopharma.

Market Segmentation & Coverage

This research report categorizes the Anti-vascular Endothelial Growth Factor Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Therapeutic Type, market is studied across Monoclonal Antibodies and Tyrosine Kinase Inhibitors.
  • Based on Route of Administration, market is studied across Intravitreal Injections and Oral Administration.
  • Based on Indication, market is studied across Diabetic Macular Edema, Retinal Vein Occlusion, and Wet Age-Related Macular Degeneration.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in the prevalence of ophthalmic diseases
      • 5.1.1.2. Increasing number of geriatric population with eye disorders
      • 5.1.1.3. Growing awareness about anti-VEGF treatment
    • 5.1.2. Restraints
      • 5.1.2.1. Unfavorable reimbursement scenario for anti-VEGF treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research activities to develop advanced therapeutics
      • 5.1.3.2. Surge in drug approvals from regulatory bodies
    • 5.1.4. Challenges
      • 5.1.4.1. Concern regarding intraocular injuries in anti-VEGF treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Anti-vascular Endothelial Growth Factor Therapeutics Market, by Therapeutic Type

  • 6.1. Introduction
  • 6.2. Monoclonal Antibodies
  • 6.3. Tyrosine Kinase Inhibitors

7. Anti-vascular Endothelial Growth Factor Therapeutics Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Intravitreal Injections
  • 7.3. Oral Administration

8. Anti-vascular Endothelial Growth Factor Therapeutics Market, by Indication

  • 8.1. Introduction
  • 8.2. Diabetic Macular Edema
  • 8.3. Retinal Vein Occlusion
  • 8.4. Wet Age-Related Macular Degeneration

9. Americas Anti-vascular Endothelial Growth Factor Therapeutics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Anti-vascular Endothelial Growth Factor Therapeutics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Anti-vascular Endothelial Growth Factor Therapeutics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Alteogen Inc.
  • 2. Amgen Inc.
  • 3. Arechar Healthcare
  • 4. Aurobindo Pharma
  • 5. Bausch Health Companies Inc.
  • 6. Bayer AG
  • 7. Biogen Inc.
  • 8. Cipla Ltd.
  • 9. Coherus BioSciences, Inc.
  • 10. Delphis Pharmaceutical India
  • 11. F. Hoffmann-La Roche AG
  • 12. Hetero Healthcare Limited
  • 13. Intas Pharmaceuticals Ltd.
  • 14. Natco Pharma Limited
  • 15. Novartis AG
  • 16. Pfenex Inc.
  • 17. Pfizer Inc.
  • 18. Regeneron Pharmaceuticals Inc.
  • 19. Samsung Bioepis
  • 20. Sandoz Canada Incorporated
  • 21. Shilpa Medicare Ltd.
  • 22. Sun Pharmaceutical Industries Inc.
  • 23. Teva Pharmaceutical Industries Ltd.
  • 24. Viatris Inc.
  • 25. Xbrane Biopharma

LIST OF FIGURES

  • FIGURE 1. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DIABETIC MACULAR EDEMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY RETINAL VEIN OCCLUSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY WET AGE-RELATED MACULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 145. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023